{"id":139138,"title":"Genedrive Expands European Adoption with Erasmus MC Implementation","publisher":"Share Talk","author":"sharetalk","published":"2026-08-04T06:52:32+00:00","modified":"2026-08-04T07:23:18+00:00","canonical_url":"https://www.share-talk.com/genedrive-expands-european-adoption-with-erasmus-mc-implementation/","markdown_url":"https://www.share-talk.com/genedrive-expands-european-adoption-with-erasmus-mc-implementation.md","json_url":"https://www.share-talk.com/genedrive-expands-european-adoption-with-erasmus-mc-implementation.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Antibiotic","biological","blood clots","chemistry","David Budd","diagnostics","Dr Gino Miele","GDR","Genedrive","Genedrive Kit","Genedrive PLC","Glasgow","Greater Manchester","hospital","infectious diseases","lab testing","Manchester","Matthew Fowler","molecular","MT-RNR1 ID Kit","NHS","Royal Albert Edward Infirmary","Royal Alexandra Hospital","Royal Bolton Hospital","Scotland","Share Talk","Stepping Hill Hospital","Tameside General Hospital","The Royal Oldham Hospital","Thermo Fisher Scientific","UK hospitals"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/5a821202-2a8f-45ab-b160-61242475f110.png?fit=1672%2C941&quality=80&ssl=1","format":"news","language":"en-GB","content":"[Genedrive PLC (AIM: GDR)](https://www.investegate.co.uk/announcement/rns/genedrive--gdr/mt-rnr1-test-implemented-in-the-netherlands/9702462) has announced that its **Genedrive® MT-RNR1 ID Kit** has been implemented at **Erasmus MC University Medical Center** in Rotterdam, expanding the international adoption of its rapid pharmacogenetic testing technology.\n\nThe kit, which is designed to help prevent antibiotic-induced hearing loss in newborn babies, entered routine use at Erasmus MC on **3 August 2026**.\n\nErasmus MC is one of Europe’s leading university medical centres and treats around **750 newborn babies each year** in its neonatal intensive care unit. The implementation is being funded by the hospital’s Pharmacogenetics International Expert Center.\n\nThe test identifies newborns carrying the **MT-RNR1 genetic variant**, which can place them at risk of profound and irreversible hearing loss if treated with aminoglycoside antibiotics.\n\nBy delivering a rapid result at the point of care, the system allows clinicians to make informed prescribing decisions without delaying urgently needed treatment for suspected sepsis.\n\nChief executive **Dr Gino Miele** said the deployment strengthened Genedrive’s presence in Europe and reflected growing international recognition of the value of rapid pharmacogenetic testing.\n\nErasmus MC becomes the first medical centre in the Netherlands to introduce the technology into routine neonatal care.\n\nThe Genedrive® MT-RNR1 ID Kit is already in clinical use across more than **20 neonatal intensive care units** in the UK and internationally, with further commercial and implementation activity progressing across Europe and the Middle East."}